This move is archived. Current quotes and coverage live on the stock page.
Get MDP alerts:
Medexus Pharmaceuticals Inc (MDP.TO) is on the rise, closing up 1.70% in the latest trading session, reflecting positive investor sentiment.
In a market where many stocks are struggling, Medexus has gained traction, finishing the day at CA$4.18. This uptick comes amid ongoing developments in the company's product offerings and strategic initiatives.
Investor takeaway: Investors may find Medexus's recent performance encouraging, especially as the company continues to focus on its flagship product, GRAFAPEX (treosulfan) for Injection.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$159.02M
52W high
$5.50
52W low
$2.51
1W change
-0.58%
Beta
1.83
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 42.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+42.2% Upside
Current Price
C$5.10
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
32.6%
Annualized
90-Day Vol
40.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.10
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.41 | C$4.84 โ C$6.06 |
| 60 trading days | C$5.74 | C$4.90 โ C$6.74 |
| 90 trading days | C$6.10 | C$5.02 โ C$7.41 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Medexus Pharmaceuticals Inc Gains 1.70% in One Day
With a market cap of CA$130.8 million, Medexus's stock performance shows investor optimism about its future prospects.
Bull case
The recent gains could signal growing confidence in Medexus's business strategy and product pipeline. Investors are particularly interested in updates regarding GRAFAPEX and the companyโs participation in investor conferences.
Bear case
Despite the positive movement, Medexus still faces challenges, including a negative profit margin and the risks that come with being a small-cap pharmaceutical company.
Market Performance Overview
Advertisement
Medexus Pharmaceuticals Inc closed the last trading session at CA$4.18, marking a 1.70% increase. This performance stands out in a volatile market, indicating a potential shift in investor confidence.
Strategic Developments
The company's focus on GRAFAPEX (treosulfan) for Injection continues to drive interest. Recent updates and participation in investor conferences may further boost investor sentiment, providing a clearer picture of Medexus's direction.
Looking Ahead
As Medexus navigates the complexities of the pharmaceutical landscape, investors should keep an eye on upcoming announcements and market reactions to gauge the sustainability of this upward trend.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
